Dicerna Archives -

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover deal

https://pharmaphorum.com/news/novo-nordisk-snaps-up-rnai-partner-dicerna-in-3-3bn-takeover-deal/

News/ News/ R&D

Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trial

Richard Staines Antios, Dicerna, GlaxoSmithKline, hepatitis B, infectious diseases, Ionis, Roche 0 Comment

Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its

Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trial

https://pharmaphorum.com/news/race-for-hepatitis-b-drug-intensifies-as-antios-raises-96m-for-phase-2-trial/

News/ News/ R&D

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Phil Taylor Diabetes, Dicerna, gene silencing, hepatology, NASH, Novo Nordisk, RNAi 0 Comment

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

https://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/

Market Access/ News/ News

FDA approves Alnylam’s ultra-rare disease drug Oxlumo

Richard Staines Alnylam, Dicerna, pricing, Rare diseases, regulation 0 Comment

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1),

FDA approves Alnylam’s ultra-rare disease drug Oxlumo

https://pharmaphorum.com/news/fda-approves-alynlams-ultra-rare-disease-drug-oxlumo/

Market Access/ News/ News

Alnylam files its third RNAi drug lumasiran in rare kidney disease

Phil Taylor Alnylam, Dicerna, lumasiran, nephrology, OxThera, rare disease 0 Comment

Gene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3

Alnylam files its third RNAi drug lumasiran in rare kidney disease

https://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/

News/ News/ R&D

Novo bolsters R&D pipeline with RNAi therapies from Dicerna

Richard Staines Dicerna, NASH, Novo Nordisk, RNAi therapy 0 Comment

Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to

Novo bolsters R&D pipeline with RNAi therapies from Dicerna

https://pharmaphorum.com/news/novo-bolsters-rd-pipeline-with-rnai-therapies-from-dicerna/

The diagnosis Hepatitis written on a clipboard

News/ News/ R&D

Roche swoops on Dicerna’s gene-silencing hepatitis B drug

Phil Taylor Dicerna, hepatitis B, licensing, RNA interference, Roche 0 Comment

Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront

Roche swoops on Dicerna’s gene-silencing hepatitis B drug

https://pharmaphorum.com/news/roche-swoops-on-dicernas-gene-silencing-hepatitis-b-drug/

News/ News/ R&D

Dicerna agrees another gene-silencing deal, this time with Lilly

Phil Taylor Dicerna, Lilly, rna 0 Comment

Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake

Dicerna agrees another gene-silencing deal, this time with Lilly

https://pharmaphorum.com/news/dicerna-agrees-another-gene-silencing-deal-this-time-with-lilly/

News

Alexion joins with Dicerna to develop RNAi therapies for complement diseases

Richard Staines Alexion, Dicerna, R&D, Rare diseases 0 Comment

Alexion has announced a collaboration with Dicerna Pharmaceuticals to discover and develop RNA interference therapies for diseases caused

Alexion joins with Dicerna to develop RNAi therapies for complement diseases

https://pharmaphorum.com/news/alexion-joins-with-dicerna-to-develop-rnai-therapies-for-complement-diseases/

Trending

Dicerna

Login